Diffuse large B-cell lymphoma is a heterogeneous group of diseases with different responses to therapy. Targeting mTOR (mammalian target of rapamycin) offers a new approach to improve the treatment. mTOR inhibitors are being developed and are in clinical use in mantle cell lymphoma therapy and clinical trials are ongoing in other high-grade lymphomas as well. However, there is limited data about mTOR activity and the expression of its different complexes in diffuse large B-cell lymphomas. Tissue microarray blocks were constructed from paraffin-embedded biopsy specimens. More than 700 immunohistochemical stainings (mTOR signaling-related proteins and phosphoproteins, markers for lymphoma classification) were evaluated from 68 diffuse large B-cell lymphoma biopsies from conventionally treated and followed patients. Approximately 30% of cases were characterized as germinal center-derived diffuse large B-cell lymphomas, which showed virtually no mTOR activity, as determined by phospho-ribosomal S6 expression, the most sensitive marker of mTOR activity. In about 80% of non-germinal center-derived diffuse large B-cell lymphoma cases, positivity of mTOR-related phosphoproteins was observed, denoting mTOR activity. Moreover, Rictor (a characteristic protein of the mTOR complex2) was overexpressed in 43% of all diffuse large B-cell lymphomas and in 63% of mTOR-active nongerminal center diffuse large B-cell lymphoma samples. Rictor overexpression with mTOR activity indicated significantly worse survival for patients than mTOR inactivity or mTOR activity with low Rictor expression. These results suggest that mTOR activity is characteristic in most non-germinal center-derived diffuse large B-cell lymphomas with potentially variable mTOR-inhibitor sensitivity. Taken together, mTOR inhibitors may be useful in addition to regular therapy in diffuse large B-cell lymphomas, however, patient and inhibitor selection criteria must be carefully considered.
Diffuse large B-cell lymphoma is an aggressive and heterogeneous entity characterized by the presence of large cells with mature B-cell phenotype. The therapy of diffuse large B-cell lymphoma has greatly improved in the past 10 years. [1] [2] [3] Several studies confirm that the inclusion of rituximab in the protocols increases response rate, progression-free survival and overall survival. Based on the metaanalysis of five studies with rituximab, clinical outcome was significantly better for germinal center phenotype diffuse large B-cell lymphoma patients than for those with active B-cell origin, ie, the non-germinal center subtype. However, treatments still fail in 30-40% of patients, especially in the non-germinal center group. 4 Patients may benefit from novel strategies of targeted therapybased on the better understanding of diffuse large B-cell lymphoma.
The PI3K/Akt/mTOR (phosphoinositide-3-kinase/ Akt-protein kinase B/mammalian target of rapamycin) pathway-one of the numerous signaling mechanisms-has become an important target for cancer therapy. [5] [6] [7] [8] This study focuses on mTOR, a serine-threonine kinase, a regulator and integrator of many cellular functions, eg, survival, proliferation, protein translation and cellular metabolism. 9 mTOR can form two distinct complexes (mTORC1 and mTORC2), which can be activated by various stimuli (growth factors, hormones, metabolic stress, etc). The activity of these complexes depends on the phosphorylation status of mTOR at S2448. mTORC1/C2 complexes share common members but possess also specific elements such as Raptor (in mTORC1) and Rictor (in mTORC2). 10, 11 Activated mTOR phosphorylates key translational regulators: initiation factor 4E-binding protein (4EBP1), 70 kDa S6 ribosomal protein kinase (p70S6K) and subsequently ribosomal S6 protein. 12 mTORC1 is sensitive to currently used mTOR inhibitors (rapamycin, temsirolimus and everolimus). The function and regulation of mTORC2 and its response to rapamycin or rapalogs (relatives of rapamycin) still remain conflicting, and may vary in different cell types. 13, 14 mTOR inhibitors are approved against renal cell cancer (clear-cell variant) and mantle cell lymphoma. Many trials intend to achieve clinical response in different lymphomas, including diffuse large B-cell lymphoma, but the success rate has been rather limited so far. Factors behind responsiveness or resistance are also largely obscure at present. [15] [16] [17] The analysis of targeted molecules (expression levels, phosphorylation and/or localization of proteins, indicating their activation state) or of proteins related to their activity can help predict the outcome of molecular targeted therapy. Therefore we need to find markers to determine the activation level of the mTOR pathway and to predict response to mTOR inhibitor therapy in diffuse large B-cell lymphomas for the selection of patients who may further benefit from mTOR inhibition. 17, 18 Materials and methods
Patients
Diffuse large B-cell lymphoma cases were diagnosed between 1995 and 2009 at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University.
Originally, 68 patients were selected retrospectively for this study (males and females in equal number; mean age: 59 years, range 13-87 years), who were treated with conventional R-CHOP, R-CEOP or CHOP therapy. Sixty-five percent of the patients had a high international prognostic index score (IPI: 3-4) and seventy-two percent had stage III-IV disease. The 2-year overall survival was 63% in these 68 cases. All cases were eligible for immunohistochemistry and data analysis; however, some patients-those who died within 2 months after the beginning of the therapy, those who died of diseases other than lymphoma, or if the period from diagnosis was o5 years-were excluded from detailed 5-year survival analysis. Finally, 52 cases were appropriate for statistical evaluation. Overall survival was 62% in this group; mean and median survival times were 47 and 42 months, but dependent on international prognostic index scores (mean: 60 months, median: 60 months for international prognostic index 0-2; mean: 37 months, median: 28 months for international prognostic index 3-4). Diffuse large B-cell lymphoma classification was performed based on Han's, Tally's and Choi's algorithms as well. 19 
Tissue Microarray and Immunohistochemistry
Formalin-fixed paraffin-embedded tissue blocks from each patient were reviewed and representative areas (rich in lymphoma cells) were designated. A minimum of two cores with a diameter of 2 mm were selected from different areas of each block and three tissue microarray blocks were constructed (70 tissue samples/each). In some cases a third core or other tissues as 'controls' (reactive lymph nodes) were included.
Antigen retrieval was done on 3-5-mm thick sections by cooking in a pressure cooker for 20-30 min (buffers: 10 mM citrate pH ¼ 6; 10 mM Tris-EDTA pH ¼ 9; Target Retrieval Solution buffer, Dako, BOND Epitope Retrieval Solution 2 pH ¼ 8.5-9, Leica). Slides were incubated with primary antibodies directed against phosphorylated-mTOR, phosphorylated-S6, phosphorylated-4EBP1 (Cell Signaling Technology; p-mTOR: #2976, 1:100; p-S6: #2211, 1:150; p-4EBP1: #2855, 1:200), phosphorylated-p70S6K (p-p70S6K, 1:200; this antibody was a kind gift of Dako), Rictor (Bethyl Laboratories #00429, 1:500), Raptor (Novus #110-57455, 1:100), GCET1 (Abcam #68889, 1:100), FOXP-1 (Abcam #32010, 1:500), LMO-2 (Abcam #64139, 1:1000). Immunodetection was performed with Novolink secondary detection system (Novocastra) and diaminobenzidine substrate, followed by hematoxylin counterstaining. Mum-1, Bcl-6 (Dako; 1:50 and 1:20, respectively), CD10 and Bcl-2 (Novocastra; 1:100 and 1:20, respectively) immunostainings were performed using the Bond Polymer Refine detection System (Leica) on a Ventana 320 automated immunostaining system. mTOR-related phosphoprotein reaction intensity (negative, 1 þ (weak)/2 þ (moderate)/3 þ (strong) positive) was agreed upon before blind evaluation of the scores. The cutoff for positivity was set at 10% of the tumor cells staining for mTOR signaling-related antibodies, based on the reproducibility of different, preliminarily tested threshold levels by trained hemato-pathologists. This morphologically detected subpopulation (10%) was considered pathologically significant, with the potential capacity to allow subclonal development. Moreover, cases were considered as mTOR active only when scores were 2 þ /3 þ for mTOR activity in diffuse large B-cell lymphomas p-S6 and for at least one additional mTOR activity related phosphoprotein. Nonmalignant, reactive lymphocytes showed a maximum positivity of 1 þ , whereas plasma cells were scored 3 þ . Staining was scored independently by two pathologists. In case of differences, a consultative discussion involving a third pathologist gave the final mark. 3DHistech Pannoramic Viewer program and Nikon E200 were used to evaluate tissue microarrays.
Overall survival distribution was estimated with the Kaplan-Meier method, log rank test and analysis of variance were calculated with SPSS software (SPSS, Chicago, IL, USA). Po0.001 was considered statistically significant.
Results
Germinal center and non-germinal center-type diffuse large B-cell lymphomas were distinguished using three different algorithms based on Mum1, CD10, bcl-6, LMO-2, FOXP-1 and GCET1 staining. The classification differed only in one case, according to Han's and Tally's versus Choi's algorithms. Considering Tally's and Han's classification, 50 out of 68 cases (74%) had a non-germinal center and 18 (26%) had a germinal center-derived phenotype. mTOR activity was verified in 42 cases (62%) by positive immunostaining for p-S6-the most sensitive marker of mTOR activity-and at least one additional positivity for any of the following: p-mTOR, p-4EBP1 or p-p70S6K. Interestingly, the two subtypes showed remarkable differences. Germinal center-derived samples expressed virtually no mTOR activity: 16 were negative for p-S6 and only 2 samples showed moderate p-S6 reaction. On the contrary, 80% of non-germinal center-derived cases were considered mTOR active (Figure 1 and 2 correlation between mTOR activity and other clinical data (summarized in Table 1 ). In addition to mTOR activity, we parallelly evaluated Raptor (characteristic for mTORC1) and Rictor (characteristic for mTORC2) immunohistochemical stainings in 68 diffuse large B-cell lymphoma cases and in reactive lymphoid tissues. Reactive lymphoid tissues showed weak staining intensity (1 þ ) for both proteins. Raptor was expressed (1 þ or 2 þ ) in every mTOR-active case, and it was moderate (2 þ ) in about 24% of mTOR-active diffuse large B-cell lymphomas. Rictor was overexpressed (3 þ staining intensity) in 29 diffuse large B-cell lymphoma samples (43%), and this was accompanied by mTOR activity in almost all (25 non-germinal center and 1 germinal center originated) cases. In three germinal center-derived cases only Rictor was positive, with no mTOR activity. However, when Rictor expression was analyzed separately, we found that mTOR-active non-germinal center diffuse large B-cell lymphoma cases (n ¼ 40) could be further divided into Rictor-overexpressing (3 þ staining; 25 out of 40) and nonRictor-overexpressing (0-2 þ staining; 15 out of 40) groups (Figure 1) . mTOR activity and Rictor expression was statistically analyzed along with 5-year survival data in 52 diffuse large B-cell lymphomas. Patients with a 5-year follow up had significantly higher overall survival when mTOR was inactive (67%) than when it was active (41%) (Figure 3. ). Median survival time was also remarkably longer in the mTOR-inactive than in the mTOR-active group (60 vs 28 months, respectively). Interestingly, Rictor expression segregated the mTOR-active group into two subgroups with distinctive prognoses. mTOR-active and Rictoroverexpressing (3 þ ) diffuse large B-cell lymphoma patients had the worst prognosis: 5-year overall survival was 32% and median survival time was 21 months. Survival time and overall survival for patients with active mTOR and weak or a maximum of 2 þ Rictor expression was basically the same as for the mTOR-inactive group (overall survival was 77% and median survival time was more than 60 months in mTOR-inactive and mTOR-active patients with low Rictor expression) ( Figure 3 ).
Discussion
In our study, we examined the activity of mTOR signaling in well-characterized and followed diffuse large B-cell lymphoma cases, and we found that germinal center-derived diffuse large B-cell lymphoma showed practically no mTOR activity; however, mTOR activity was observed in about 80% of nongerminal center-type lymphomas. Our results suggest that mTOR activity is characteristic in most (but not all) non-germinal center-derived diffuse large B-cell lymphomas. Although the importance of mTOR activity in the production of survival factors is well demonstrated by mTOR-mediated cyclinD1 expression in mantle cell lymphoma, 20 we found no statistical correlation between mTOR activity and the expression of the examined pro-proliferative or anti-apoptotic factors (bcl-2 and bcl-6) (data not shown). However, significant correlation between germinal center/non-germinal center subtypes, and mTOR activity was detected in our 68 diffuse large B-cell lymphoma cases. These results correlate well with the work of others, where p-p70S6K and CDC2/cdk1 (mTOR-related proteins) were proposed as relevant targets in diffuse large B-cell lymphoma cells, 21 supporting the possibility of complementing or replacing the currently used R-CHOP therapy. 2, 4, 22 Targeting mTOR may be similarly or even more effective. Rictor, the characteristic protein of mTORC2 complex, was overexpressed in 29/68, 43% of cases. Rictor and Raptor expression has not been characterized in diffuse large B-cell lymphomas previously; nuclear p-mTOR staining was considered the sign of mTORC2 activity in two diffuse large B-cell lymphoma cases by others, 15 however, this observation remains controversial. Concerning intracellular localization, nuclear-in addition to cytoplasmicp-mTOR reaction was observed in o5% of the cells in our study and we did not attribute this to mTORC2 activity-especially because Rictor (an element of the mTORC2 complex) was present only in the cytoplasm, as functionally expected and reported also by others. 23 One of the key targets of mTORC2 is Akt. 23 Akt has been reported to show activity in about 30-40% of diffuse large B-cell lymphoma cases, 24, 25 which is in the same range as overall Rictor expression in our study. Rictor expression and Akt activity may explain the inefficiency of rapamycin analog (rapalog) therapy in recent phase I/II studies, where targeting mTORC1 resulted in 28-32% response rates in high-grade lymphomas. Further improvement may be expected using drugs effectively inhibiting both mTOR-complexes (so called dual inhibitors). 16, 17, 26, 27 Taken together, we found that diffuse large B-cell lymphomas with active mTOR-signaling have a poor prognosis, and Rictor overexpression may predict low or no responsiveness to conventional rapalog (mTORC1 inhibitor) therapy in these cases. Predicting the sensitivity and the potential cost/benefit of mTOR-inhibitor treatment requires individual attention in every patient. Careful study design and result analysis is also crucial in recent and future clinical trials with mTOR inhibitors. We suggest that the evaluation of active mTORC1 (Raptor þ p-mTOR) to active mTORC2 (Rictor þ p-mTOR) ratio in diffuse large B-cell lymphoma may help identify patients suitable for targeted therapy, who can expect longer survival or potential cure with conventional mTORinhibitor therapy, and warn if dual inhibitors are required in order to provide therapeutical benefit.
